Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stricter Checks on Medicines

This article was originally published in PharmAsia News

Executive Summary

Xinhua News Agency (01/28/07) Starting in the second half of 2007, Chinese authorities plan to review close to 170,000 drug approvals in order to retest drugs, examine their market track record in official databases, and remove inadequate drugs from the Chinese marketplace. The review will apply to drugs that won Good Manufacturing Practice (GMP) certificates in 2004 and 2005. The Chinese pharmaceutical industry contains numerous companies that copy existing products and sell them under a new name for higher than usual prices. China Galaxy Securities analyst Liu Yanming says revoking licenses will improve market competitiveness, spur more research and development, and likely lead to mergers in China's drug industry. (Click here for more

You may also be interested in...



Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?

Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business. 

Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

UsernamePublicRestriction

Register

SC065661

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel